Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.9%, DAX +1.7% CAC +1.4%, SMI +1.1%

Jun 15 ,2026

  • Synopsis

    • European equity markets set to open broadly higher, extending last week's gains when the STOXX Europe 600 closed up +1.69%.

    • Ahead of the European market open this morning, markets in risk-on mode after US and Iran confirmed deal to end conflict (including in Lebanon) with signing ceremony scheduled for 19-Jun. Trump said Strait of Hormuz shipping will resume after deal signed and without tolls. US will end naval blockade in return. No details on MoU text, which Iran says will be published after signing ceremony. Previous press leaks noted MoU will include 60-day ceasefire extension, during which discussions will be held primarily on issues such as Iran's nuclear program and sanctions relief. Addressing uranium stockpiles and extent/conditionality of sanctions relief remain open questions.

    • Asian equities rallying Monday after US and Iran agreed to end hostilities. Tech-heavy benchmarks in Japan, South Korea and Taiwan outperforming. Greater China markets also higher in early trade. S&P 500 futures advancing. Bond markets stronger with Treasury and JGB yields declining across the curve. Crude under pressure, near two-month low. Gold, silver and Bitcoin rallying alongside equities. Dollar weakening against euro. Airline stocks likely to be beneficiaries of the sharp drop in oil this morning.

    • Voters in Switzerland have rejected a proposal to limit the country's population to 10 million (BBC, Reuters ). Results showed nearly 55% of participants voted against and 45% voted for, with a turnout of 60% of the population. The proposal came from the right-wing Swiss People's Party, which has long campaigned on an anti-immigration platform. Reuters notes the vote, which was likened to Britain's 2016 Brexit referendum, had put businesses on edge due to concerns it could end the free movement of labour between Switzerland and the EU, the country's main trading partner.

    • European macro data releases out today include Italy Apr trade balance, Eurozone Apr trade balance, industrial production, Switzerland May PPI, Consumer Sentiment - SECO, Sweden May unemployment rate, Norway May trade balance, Finland May CPI, Netherlands Apr trade balance

    • On the corporate front, Allianz is emerging as the most likely buyer of HSBC Life Singapore, while Holcim secured EC approval for its Xella acquisition and Bouygues CEO expressed confidence the SFR deal can clear regulators. Bridgepoint is preparing to sell MyDefence in a ~$1B deal and Frasers Group launched an unconditional A$0.65/share cash offer for Accent Group, whose board is recommending no action. In healthcare, AstraZeneca secured FDA approval for Truqap in PTEN-deficient prostate cancer, Sanofi received accelerated approval for Tzield in Stage 3 Type 1 diabetes, and UnitedHealth's OptumRx settled with the FTC on insulin pricing. Elsewhere, Publicis resolved its ad tech dispute with The Trade Desk, Sainsbury's is reportedly searching for a new chairman, and Worldline completed a 40-for-1 reverse share split.

    • UK homebuilders face a tough open after JPMorgan downgraded both Taylor Wimpey and Vistry to underweight, Rightmove posted its sharpest June price decline in 14 years, and Vistry is offering staff voluntary redundancy to preserve cash - all against a broader backdrop of mounting inflation anxieties ahead of the Bank of England's rate decision.

    • In central banks, Bundesbank's Nagel speech at 9:00CET at Frankfurt Euro Finance Summit. ECB's Lagarde pre-recorded opening keynote speech at 9:30CET, Cipollone chairs session at 9:50 at ECB conf "Money in transition: digitalisation and innovation in payments". Portugal central bank releases economic bulletin with related press conf by governor Pereira. Austria central bank's Kocher introductory remarks at event at 16:00CET title 'Central Banking in an Era of Geopolitical Uncertainty'. There's the publication at 10:00CET of the latest ECB survey of monetary analysts. Belgium central bank webinar at 14:00CET following the release on 12-Jun of it's latest economic projections. G7 summit in Evian-les-Bains (through Wed). In political events, EU-Egypt Association Council with EU's Šuica among the attendees as well as EU Foreign Affairs Council chaired by EU's Kallas with EU's Šuica among the attendees, European Aviation Strategy Summit and Green Budgeting Conf: Towards performance budgeting. In UK, MPs questions on housing, communities and local government, whilst committee topics include carbon budget seven at 16:00BST (government ministers) and deterrence in an age of Russian aggression at 16:30. Norway's transport minister Nygård will hold a dialogue meeting with rental companies and the largest municipalities about too many accidents with electric scooters. EU's Dombrovskis participates in the Recovery and Resilience Dialogue with EP committees at 20:30CET (livestream) and also participates in the ECB conf on "Fostering Digital Finance in Europe".

    • This week sees SNB and BOE interest rate decisions, G7 Summit, EU leaders meeting, IEA oil market report, Makerfield by-election in the UK, Germany Jun ZEW survey as well as a trading statement from Tesco (TSCO.LN)

  • Politics/Macro/World News

    • Anxieties over inflation risk mount ahead of Bank of England rate-setting decision (FT)

    • UK, France, Germany Ready to Lift Relevant Iran Sanctions (Bloomberg)

    • Average price of property coming to market falls by (0.6%), the biggest June fall in fourteen years (Rightmove )

  • Top company news

    • Earnings/updates

      • PGHN.SW (Partners Group Holding) -- Partners Group issues statement regarding its evergreen vehicles

      • FHZN.SW (Flughafen Zuerich) -- announces start of commercial operations at Noida International Airport; reaffirms FY guidance

      • ATS.AV (AT & S Austria Technologie & Systemtechnik) -- raises FY guidance

      • Also reporting today

        • Earnings:

          • DACHs: Addex Therapeutics (ADXN.SW)

          • UK: Peel Hunt (PEEL.LN), Team Internet Group (TIG.LN)

        • Traffic: Aeroport de Paris (ADP.FP)

        • CMD/Events: Medacta Group (MOVE.SW), Rederiaktiebolaget Gotland (GOTL.A.SS) 10:1 stock split, Schaeffler (SHA0.GR) Automotive Symposium (through Tue)

    • M&A

      • ALV.GR (Allianz) -- is most likely buyer of HSBC Life Singapore - Bloomberg

      • BANQ.BB (Banqup Group) -- announces strategic simplification plan and launch of process to explore strategic alternatives; FY financial guidance remains on track

      • HOLN.SW (Holcim) -- EC approves Holcim's acquisition of Xella, subject to conditions

      • EN.FP (Bouygues) -- believes deal to acquire SFR can win regulatory approval - FT, citing CEO

      • HLS.AU (Healius) -- EQT added to list of parties looking at Healius's Agilex Biolabs - The Australian

      • BPT.LN (Bridgepoint Group) -- Bridgepoint preparing to sell MyDefence in ~$1B (£743M) deal - FT

      • FRAS.LN (Frasers Group), AX1.AU (Accent Group) -- Frasers Group launches on-market unconditional cash offer to acquire Accent Group at A$0.65/sh

        • AX1.AU (Accent Group) -- recommends shareholders take no action in relation to offer from Frasers Group

    • Healthcare

      • JNJ (Johnson & Johnson) -- announces new TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data that demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

      • UNH (UnitedHealth Group) -- OptumRx reaches settlement with FTC on insulin pricing, withdraws from adjudication

      • AZN.LN (AstraZeneca) -- AstraZeneca's Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

      • AZN.LN (AstraZeneca) -- Follow-up: FDA approves Truqap and a companion diagnostic for mHSPC

      • SAN.FP (Sanofi) -- FDA grants accelerated approval for Tzield sBLA for Stage 3 T1D

      • SAN.FP (Sanofi) -- issues press release on FDA approval of Tzield as disease-modifying therapy for patients with stage 3 T1D

      • ROP.SW (Roche Holding) -- Roche confirms FDA approval for Ventana PTEN approval for prostate cancer companion Dx

      • GMAB.DC (Genmab) -- announces Epcoritamab Monotherapy and epcoritamab-based combination regimens demonstrate high response rates in elderly patients with newly diagnosed diffuse large b-cell lymphoma

      • RYTM (Rhythm Pharmaceuticals) -- presents interim six-month data from phase 2 trial of Setmelanotide in patients with prader-willi syndrome (PWS) at ENDO 2026

      • HLUN.B.DC (H. Lundbeck) -- presents preliminary Phase II Part A data from ongoing study evaluating asedebart (Lu AG13909) in adults with Cushing's disease at ENDO 2026

      • IVA.FP (Inventiva) -- completes steps of transactions previously announced on 2-Jun-26

      • HNSA.SS (Hansa Biopharma) -- appoints Adam Cutler as new CFO effective 22-June

    • Other

      • VTY.LN (Vistry Group) -- offers staff voluntary redundancy to preserve cash -- Sunday Times, FT

      • PUB.FP (Publicis Groupe) -- Publicis and The Trade Desk resolve dispute related to hidden ad tech fees - AdAge

      • DSY.FP (Dassault Systemes) -- refinances its €750M revolving credit facility

      • SBRY.LN (J Sainsbury) -- looking for successor to chairman Martin Scicluna - Sky News

      • WLN.FP (Worldline) -- completes 40-for-1 reverse share split

      • Estimated weekend box office revenues in US, Canada $117.5M, (23.6%) y/y - Box Office Mojo

  • Key rating changes

    • Upgrades

      • Macquarie upgrades GGP.LN

      • CRBN.NA (Corbion) -- to buy from hold at Berenberg

      • BEAN.SW (BELIMO Holding) -- to overweight from equal-weight at Morgan Stanley

      • BGN.IM (Banca Generali) -- to buy from hold at Jefferies

      • HLMA.LN (Halma) -- to outperform from neutral at BNP Paribas Exane

      • ATS.AV (AT & S Austria Technologie & Systemtechnik) -- to neutral from underperform at Oddo

      • SWON.SW (SoftwareONE Holding) -- to outperform from neutral at BNP Paribas Exane

    • Downgrades

      • TELIA.SS (Telia Co.) -- to sell from hold at Berenberg

      • TW.LN (Taylor Wimpey) -- to underweight from neutral at JPMorgan

      • VTY.LN (Vistry Group) -- to underweight from neutral at JPMorgan

      • UCB.BB (UCB) -- to equal weight from overweight at Barclays

  • Data

    • Nikkei +4.74% to 69148.68

    • Hang Seng +0.57% to 24858.67

    • Shanghai Composite +1.32% to 4084.68

    • S&P futures +93.5 vs prior close of 7435.0

    • €-$ +0.0039 or +0.34% to 1.1617

    • $-¥ (0.04) or (0.03%) to 160.07

    • €-¥ +0.56 or +0.30% to 185.91

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.